TTC17 and breast cancer: demonstrated that proto-oncogenic isozyme sphingosine kinase 1 depletion in prostate and BC cells led to the upregulation of TTC17, recognized as one of the cellular “compensatory” responses, and it potentially influences sphingosine kinase inhibitor efficacy [47].